Jane Street’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-4,734
| Closed | -$341K | – | 12778 |
|
|
2025
Q4 | $341K | Sell |
4,734
-26,489
| -85% | -$1.71M | ﹤0.01% | 8534 |
|
|
2025
Q3 | $1.36M | Sell |
31,223
-21,269
| -41% | -$860K | ﹤0.01% | 5676 |
|
|
2025
Q2 | $1.49M | Buy |
52,492
+22,456
| +75% | +$669K | ﹤0.01% | 4911 |
|
|
2025
Q1 | $887K | Sell |
30,036
-36,528
| -55% | -$1.14M | ﹤0.01% | 5797 |
|
|
2024
Q4 | $1.94M | Sell |
66,564
-154
| -0.2% | -$6.44K | ﹤0.01% | 4164 |
|
|
2024
Q3 | $3.06M | Sell |
66,718
-95,321
| -59% | -$4.14M | ﹤0.01% | 3681 |
|
|
2024
Q2 | $6.62M | Buy |
162,039
+50,125
| +45% | +$1.44M | ﹤0.01% | 2577 |
|
|
2024
Q1 | $2.86M | Buy |
111,914
+41,659
| +59% | +$653K | ﹤0.01% | 3483 |
|
|
2023
Q4 | $636K | Sell |
70,255
-100,397
| -59% | -$671K | ﹤0.01% | 6353 |
|
|
2023
Q3 | $1.09M | Buy |
170,652
+8,392
| +5% | +$72.3K | ﹤0.01% | 5052 |
|
|
2023
Q2 | $1.8M | Buy |
162,260
+94,773
| +140% | +$1.19M | ﹤0.01% | 4317 |
|
|
2023
Q1 | $1.04M | Buy |
67,487
+50,397
| +295% | +$1.11M | ﹤0.01% | 4927 |
|
|
2022
Q4 | $379K | Buy |
+17,090
| New | +$255K | ﹤0.01% | 6619 |
|
|
2022
Q3 | – | Sell |
-45,821
| Closed | -$666K | – | 10339 |
|
|
2022
Q2 | $666K | Buy |
+45,821
| New | +$682K | ﹤0.01% | 6219 |
|
|
2021
Q4 | – | Sell |
-11,085
| Closed | -$273K | – | 10709 |
|
|
2021
Q3 | $273K | Buy |
+11,085
| New | +$241K | ﹤0.01% | 8372 |
|
|
2020
Q3 | – | Sell |
-14,182
| Closed | -$401K | – | 7801 |
|
|
2020
Q2 | $401K | Buy |
+14,182
| New | +$409K | ﹤0.01% | 5400 |
|
Other funds holding RNAM
Jane Street's RNAM Position: Q1 2026 in Review
Jane Street sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 4,734 shares — an estimated $341K sold.
Jane Street first reported a position in RNAM in Q2 2020 and held it in 16 quarters. The position peaked at $6.62M in Q2 2024. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- Jane Street reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- Jane Street sold 4,734 Avidity Biosciences shares in Q1 2026, an estimated $341K.
- Jane Street first reported a position in Avidity Biosciences in Q2 2020 and held it in 16 quarters.
- Jane Street's Avidity Biosciences position peaked at $6.62M in Q2 2024.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.